This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Avi Kapoor 1 month ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsDowngradesPrice Target
Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Baird analyst Joel Beatty downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) from Outperform to Neutral and cut the price target from $40 to $16. Ultragenyx Pharmaceutical closed at $26.53 on Wednesday. See how other analysts view this stock.
- Rothschild & Co analyst Simon Baker downgraded Moderna Inc (NASDAQ:MRNA) from Neutral to Sell and raised the price target from $40 to $81. Moderna shares closed at $150.81 on Wednesday. See how other analysts view this stock.
- B of A Securities analyst George Staphos downgraded Sonoco Products Co (NYSE:SON) from Buy to Neutral and slashed the price target from $69 to $60. Sonoco closed at $54.74 on Wednesday. See how other analysts view this stock.
- Evercore ISI Group analyst Liisa Bayko downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) from Outperform to In-Line and lowered the price target from $34 to $16. Ultragenyx Pharmaceutical shares closed at $26.53 on Wednesday. See how other analysts view this stock.
Considering buying SON stock? Here’s what analysts think:
Photo via Shutterstock